Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069823 · ClinicalTrials.gov registry record · Phase 3
Study of Acid Reflux in Asthma
A Phase 3 study of Asthma and Lung Diseases, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
- 20
- Study locations
NCT00069823 is a Phase 3 study of Asthma and Lung Diseases that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 403 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00069823, a Phase 3 study of Asthma and Lung Diseases, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
Conditions Studied
Interventions
- DRUG Esomeprazole
- DRUG Placebo proton pump inhibitor
Study Locations (20)
New York
- North Shore-LIJ Medical Center - New Hyde Park
- NYU School of Medicine - New York
- New York Medical College - Valhalla
Florida
- Nemours Childrens Clinic - Jacksonville
- University of Miami - Miami
Missouri
- Univ of MO Kansas City School of Medicine - Kansas City
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Diego - San Diego
Colorado
- National Jewish Medical and Research Center - Denver
Georgia
- Emory University - Atlanta
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069823
The ClinicalTrials.gov registry entry for NCT00069823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (74% lower). The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Esomeprazole is the first listed.
NCT00069823 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00069823 about?
NCT00069823 is a clinical study titled "Study of Acid Reflux in Asthma". The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
What is the current status of trial NCT00069823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2003-09. Estimated completion is 2008-05.
What conditions does trial NCT00069823 study?
This clinical trial studies the following conditions: Asthma, Lung Diseases, Lung Diseases, Obstructive.
What interventions are being tested in trial NCT00069823?
The interventions under investigation include: Esomeprazole (DRUG), Placebo proton pump inhibitor (DRUG).
Who is sponsoring clinical trial NCT00069823?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00069823 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.